NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Pulmonx Corporation (LUNG) Stock Analysis

Pulmonx Corporation (LUNG) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

LUNG

$2.21

−$0.05 (−2.21%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LUNG with… →

LUNG Key Statistics

As of Sep 4, 2026
Trading
Open
$2.26
Previous Close
$2.26
Day's Range
2.19–2.30
52-Week Range
1.13–2.89
Volume
220.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.34
Valuation
Market Cap
$94.92M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.12
Financials (FY)
Revenue (FY)
$90.50M+8.01%
Net Income (FY)
−$54.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−55.03%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.95M
1-Year Return
+27.01%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
586.48K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LUNG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025−67.45%
2024−46.75%
2023+51.25%
2022−73.71%
2021−53.54%
2020 (partial year)+75.58%

As of September 4, 2026.

LUNG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$90.50M−$54.00M−59.7%
2024$83.79M−$56.39M−67.3%
2023$68.68M−$60.84M−88.6%
2022$53.66M−$58.92M−109.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$90.50M$67.14M−$53.66M−$54.00M−59.7%
2024$83.79M$62.00M−$57.70M−$56.39M−67.3%
2023$68.68M$50.75M−$61.94M−$60.84M−88.6%
2022$53.66M$39.87M−$58.64M−$58.92M−109.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LUNG Valuation vs Medical Devices Median

Median of 151 stocks
MetricLUNGMedical Devices medianvs median
P/S ratio1.092.9864% below
Profit margin−55.03%−1.69%53.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pulmonx Corporation (LUNG) at $94.92M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 296 employees.

Over the past 52 weeks the price has ranged from $1.13 to $2.89. The most recent close on file for LUNG is $2.21, dated September 4, 2026. That is −$0.05 (−2.21%) against the previous close. The latest close sits 95.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $90.50M. Against the prior fiscal year total of $83.79M, that is a change of +8.01%. The same year closed with a net loss of $54.00M. Profit margin runs at −55.03%. That is 53.3 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −1.12.

Across the 4 fiscal years on file, revenue moves from $53.66M in 2022 to $90.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.09. On price-to-sales that is 63.53% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.34. Daily returns over the trailing 5 years annualize to a volatility of 83%. The trailing one-year price return is +27.01%. Across 5 years the annualized return works out at −44.45%.

Growth & Income

No dividend is on file for LUNG.

So far in 2026 the price is 0.00%. Across the complete calendar years on file, 2023 returned +51.25% and 2022 returned −73.71%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Pulmonx Corporation (LUNG) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pulmonx Corporation LUNG $94.92M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Pulmonx Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pulmonx Corporation

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Visit website →